At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBE INVESCO BIOTECHNOLOGY & GENOME ETF
Market Closed 10-09 16:00:00 EDT
96.90
+2.64
+2.80%
盘后96.77
-0.13-0.13%
19:30 EDT
High96.90Low94.43Vol2.95K
Open94.43D1 Closing94.25Amplitude2.62%
Mkt Cap423.44MTradable Cap423.44MTotal Shares4.37M
T/O284.08KT/O Rate0.07%Tradable Shares4.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data
Simply Wall St.  ·  10-10 15:30
11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data
Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  10-10 04:34
Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains
U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie
Reuters  ·  10-10 01:44
U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie
Vertex Pharmaceuticals to present data on Alyftrek at NACFC
TIPRANKS  ·  10-10 01:20
Vertex Pharmaceuticals to present data on Alyftrek at NACFC
Vertex Says Interim Alyftrek Study Data Show Some CF Children Ages 2-5 Regain Pancreatic Function
Reuters  ·  10-10 01:15
Vertex Says Interim Alyftrek Study Data Show Some CF Children Ages 2-5 Regain Pancreatic Function
Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors
TIPRANKS  ·  10-10 00:30
Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors
UBS Lifts Biogen PT on Late-Stage Pipeline Catalysts; Shares Rise
Reuters  ·  10-10 00:05
UBS Lifts Biogen PT on Late-Stage Pipeline Catalysts; Shares Rise
Royalty Pharma to Report Q3 2026 Results, Host Conference Call and Webcast
Reuters  ·  10-09 20:50
Royalty Pharma to Report Q3 2026 Results, Host Conference Call and Webcast
Royalty Pharma to Announce Third Quarter 2026 Financial Results on November 4, 2026
THOMSON REUTERS  ·  10-09 20:50
Royalty Pharma to Announce Third Quarter 2026 Financial Results on November 4, 2026
Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong
Dow Jones  ·  10-09 16:33
Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong
Linical Wins $20 Million U.S. Biotech Order as FDA Environment Normalizes
TIPRANKS  ·  10-09 10:52
Linical Wins $20 Million U.S. Biotech Order as FDA Environment Normalizes
Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued
Simply Wall St.  ·  10-09 10:36
Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued
Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants
TIPRANKS  ·  10-09 07:38
Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants
Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000
Dow Jones  ·  10-09 06:30
Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000
Biogen Inc. Stock Underperforms Thursday When Compared to Competitors
Dow Jones  ·  10-09 04:55
Biogen Inc. Stock Underperforms Thursday When Compared to Competitors
Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
TIPRANKS  ·  10-09 00:31
Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
Dow's Nearly 150-Point Fall Led by Losses for Shares of Amgen, Johnson & Johnson
Dow Jones  ·  10-08 22:51
Dow's Nearly 150-Point Fall Led by Losses for Shares of Amgen, Johnson & Johnson
Amgen Stock Forecast: Pipeline Wins Strengthen Growth Story as MariTide Phase 3 Advances
TradingKey  ·  10-08 20:00
Amgen Stock Forecast: Pipeline Wins Strengthen Growth Story as MariTide Phase 3 Advances
Alnylam Pharmaceuticals (ALNY) Is Under Securities Fraud Investigation
Simply Wall St.  ·  10-08 19:30
Alnylam Pharmaceuticals (ALNY) Is Under Securities Fraud Investigation
Biogen : RBC Cuts Target Price to $256 from $260
THOMSON REUTERS  ·  10-08 18:02
Biogen : RBC Cuts Target Price to $256 from $260
No data available

Introduction

Company Name.
INVESCO BIOTECHNOLOGY & GENOME ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Issue price:
--